An Open-label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic Immune Thrombocytopenia
Latest Information Update: 14 Oct 2025
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Dova Pharmaceuticals
Most Recent Events
- 01 Oct 2025 Planned End Date changed from 31 Aug 2025 to 31 Oct 2025.
- 15 Aug 2023 Planned End Date changed from 31 Dec 2025 to 31 Aug 2025.
- 15 Aug 2023 Planned primary completion date changed from 30 Nov 2023 to 18 Jan 2024.